— PAY ATTENTION! 🚨 Eli Lilly just filed lawsuits against 6 U.S. companies selling/marketing retatrutide. But this appears to be MUCH bigger than just those six companies. (Eli Lilly and Company⁠) Lilly says it has already referred hundreds of sellers worldwide to regulators and law enforcement and is calling for action from: 💳 Payment processors 📦 Shipping companies 🌐 Online platforms ⚖️ Regulators & law enforcement U.S. Customs reportedly seized 90,000+ vials of illicit GLP-1 products in July alone. (Reuters⁠) So YES—the 6 lawsuits announced today are against U.S. companies, but Lilly’s enforcement efforts are clearly GLOBAL. 🌎 This could change the peptide industry in a BIG way. 🔬👀 #Retatrutide #Peptides #EliLilly #ResearchPeptides #GLP1 #TPLH

There’s waaaay more than this coming ! MannyFresh

🚨 GLP-1s & VISION LOSS — LET’S TALK FACTS 👁️🔬 You may have heard that “GLP-1s can cause blindness.” The research is more nuanced. NAION is a rare condition caused by reduced blood flow to the optic nerve that can result in sudden, painless vision loss. 🔴 Semaglutide (Ozempic/Wegovy): Has the strongest NAION safety signal. Observational studies have found an association, but association does not necessarily prove causation. 🟡 Tirzepatide (Mounjaro/Zepbound): Evidence is still limited and developing. ⚪ Retatrutide: Not enough long-term human data yet to determine NAION risk. It’s also important to remember that diabetes, high blood pressure, high cholesterol and sleep apnea are themselves NAION risk factors. ⚠️ Sudden, painless vision loss or a new dark/gray area in one eye requires urgent medical evaluation. 🔬 READ THE RESEARCH: JAMA Ophthalmology — 2024 Semaglutide & NAION https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255 JAMA Ophthalmology — 2025 37.1-million-person analysis https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2830475 JAMA Ophthalmology — 2026 Semaglutide vs. SGLT2 inhibitors https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2844873 EMA — 2025 NAION classified as a very rare side effect of semaglutide. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy 📚 Education over fear. Evidence over rumors. #GLP1 #Semaglutide #Tirzepatide #Retatrutide #NAION #EyeHealth #TPLH

Thought !!!?